Genentech pours $750M into new drug‑delivery device plant in Oregon; Bavarian Nordic pushes back Lyme vaccine trial

Roche’s Genentech announced a $750 million investment to build a new drug‑delivery device manufacturing facility at its Hillsboro, Oregon campus. The plant is intended to expand the company’s capacity for advanced delivery technologies.

The new site is slated to become operational in the coming years, though a specific launch date was not disclosed. The investment underscores Genentech’s focus on strengthening its manufacturing footprint in the United States.

In a separate update, Bavarian Nordic reported a delay in the clinical trial of its Lyme disease vaccine. The company did not provide a revised timeline for the study’s restart.

Both developments highlight contrasting movements in the sector, with Genentech scaling up production capabilities while Bavarian Nordic faces setbacks in its vaccine development program.